No products in the cart.
Pre-made Ramucirumab benchmark antibody ( Whole mAb, anti-KDR therapeutic antibody, Anti-FLK1/CD309/VEGFR/VEGFR2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-468
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ramucirumab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ramucirumab (LY3009806, IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.
| Products Name (INN Index) | Pre-Made Ramucirumab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody |
|---|---|
| INN Name | Ramucirumab |
| Target | KDR |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 3s34:HL/3s37:HL/3s36:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2008 |
| Year Recommended | 2009 |
| Companies | Dyax,AstraZeneca,Dana-Farber Cancer Institute,Eli Lilly,Merck Sharp & Dohme,University of Texas M. D. Anderson Cancer Center,Washington University School of Medicine |
| Conditions Approved | Colorectal cancer,Gastric cancer,Non-small cell lung cancer,Liver cancer |
| Conditions Active | Oesophageal cancer,Urogenital cancer,Biliary cancer,Carcinoid tumour,Solid tumours,Pancreatic cancer |
| Conditions Discontinued | Breast cancer,Malignant melanoma,Ovarian cancer,Prostate cancer,Renal cell carcinoma |
| Development Tech | Dyax Human Phage Display |
| Previous Name | NA |
| Gm Offical Target Name | KDR |
| Package |
Previous slide
Next slide
